John W. Mellors, MD From the October 2006 revisions to the DHHS adult and adolescent HIV treatment guidelines (appendix A): Dr. Mellors serves on the HIV Advisory Boards (and receives compensation) for: Abbott Laboratories Achillion Pharmaceuticals (this fact was discovered by accident and is not reported in his 10/06 DHHS disclosure) Gilead Sciences Merck & Co. Virco-Tibotec (a subsidiary of Johnson & Johnson, Inc.) Dr. Mellors owns stock or stock options in the following companies with HIV products in development: Achillion Pharmaceuticals Depomed, Inc. Pharmasset, Inc. Dr. Mellors owns patents or has patents pending with: Emory University National Cancer Institute University of California - San Diego University of Pittsburgh 2004 conflict of interest/competing interest disclosures for John W. Mellors From the DHHS treatment guidelines (10/29/2004) Achillion Pharmaceuticals: Stock holder Boehringer Ingelheim: HIV Advisory Board Gilead Sciences: HIV Advisory Board GlaxoSmithKline: HIV Advisory Board Idenix Pharmaceuticals: Stock holder Merck & Co.: HIV Advisory Board Pharmasset: Stock options Tibotec-Virco: HIV Advisory Board Source: see new Appendix A, "DHHS Panel on Clinical Practices for Treatment of HIV Infection Conflict of Interest Disclosure – October 2004," of the DHHS "Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents" at http://www.aidsinfo.nih.gov/guidelines (accessed March 26, 2005)